Xu Feifei, Cao Lu, Xu Cheng, Cai Gang, Cai Rong, Qi Weixiang, Wang Shubei, Shen Kunwei, Chai Weimin, Chen Jiayi
Department of Radiation Oncology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 20025, China.
Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 20025, China.
J Clin Med. 2022 Sep 1;11(17):5188. doi: 10.3390/jcm11175188.
Purpose: We sought to explore the role of nomogram-combined biomarkers, mammographic microcalcification and inflammatory hematologic markers in guiding local therapy decisions in ductal carcinoma in situ (DCIS) subgroups with different ipsilateral breast tumour recurrence (IBTR) risk. Methods: Between January 2009 and December 2018, consecutive patients with DCIS and breast conserving surgery (BCS) were enrolled and randomly assigned to a training cohort (n = 181) and internally validation cohort (n = 78). Multivariate analyses were performed to identify predictors of IBTR. Model performance was evaluated by the concordance index (C-index) and calibration plot. The time-to-event curves were calculated by the Kaplan−Meier methods and compared by the log-rank test. Results: In total, 259 patients were enrolled and 182 of them received whole breast irradiation (WBI). After a median follow-up of 51.02 months, 23 IBTR events occurred in the whole cohort. By multivariate analyses of training cohort, presence of microinvasion, Ki67 index >14%, mammographic-clustered fine linear microcalcifications and neutrophil/lymphocyte ratio before BCS (preop-NLR), >1.1 remained independent risk factors of IBTR to develop a nomogram. The C-indexes of the nomogram were 0.87 and 0.86 in the training and internal validation set, respectively. Calibration plots illustrated good agreement between the predictions and actual observations for 5-year IBTR. Cut-off values of nomogram point were identified as 53 and 115 points, which divided all patients into low-, intermediate- and high-risk groups. Significant differences in IBTR existed between low-, intermediate- and high-risk subgroups (p < 0.01). For the whole cohort and ER-positive tumours, the benefit of WBI was found only in the intermediate-risk subgroup, but not in those with low or high risk. Fourteen out of 23 IBTRs occurred outside the original quadrant and all occurred in the high-risk group. Conclusions: The novel nomogram demonstrated potential to separate the risk of IBTR and locations of IBTR. For the whole cohort and ER-positive tumours, the benefit of WBI was restricted to an intermediate-risk subgroup.
我们试图探讨列线图联合生物标志物、乳腺钼靶微钙化和炎症血液学标志物在指导不同同侧乳腺肿瘤复发(IBTR)风险的导管原位癌(DCIS)亚组局部治疗决策中的作用。方法:2009年1月至2018年12月,连续纳入接受保乳手术(BCS)的DCIS患者,并随机分为训练队列(n = 181)和内部验证队列(n = 78)。进行多变量分析以确定IBTR的预测因素。通过一致性指数(C指数)和校准图评估模型性能。采用Kaplan-Meier方法计算事件发生时间曲线,并通过对数秩检验进行比较。结果:共纳入259例患者,其中182例接受了全乳照射(WBI)。中位随访51.02个月后,整个队列中发生了23例IBTR事件。通过对训练队列的多变量分析,微浸润的存在、Ki67指数>14%、乳腺钼靶簇状细线性微钙化以及BCS前中性粒细胞/淋巴细胞比值(术前NLR)>1.1仍然是IBTR发生的独立危险因素,据此构建列线图。列线图在训练集和内部验证集的C指数分别为0.87和0.86。校准图显示5年IBTR的预测值与实际观察值之间具有良好的一致性。列线图得分的截断值确定为53分和115分,据此将所有患者分为低、中、高风险组。低、中、高风险亚组之间的IBTR存在显著差异(p < 0.01)。对于整个队列和雌激素受体(ER)阳性肿瘤,仅在中风险亚组中发现WBI的获益,低风险或高风险亚组未发现。23例IBTR中有14例发生在原象限之外,均发生在高风险组。结论:新型列线图显示出区分IBTR风险和IBTR位置的潜力。对于整个队列和ER阳性肿瘤,WBI的获益仅限于中风险亚组。